0001104659-23-100560.txt : 20230913
0001104659-23-100560.hdr.sgml : 20230913
20230913210256
ACCESSION NUMBER: 0001104659-23-100560
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230911
FILED AS OF DATE: 20230913
DATE AS OF CHANGE: 20230913
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Esposito Pamela
CENTRAL INDEX KEY: 0001744425
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 231253897
MAIL ADDRESS:
STREET 1: C/O REPLIMUNE GROUP, INC.
STREET 2: 18 COMMERCE WAY
CITY: WOBURN
STATE: MA
ZIP: 01801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
tm2325969-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-09-11
0
0001737953
Replimune Group, Inc.
REPL
0001744425
Esposito Pamela
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK DRIVE
WOBURN
MA
01801
0
1
0
0
Chief Business Officer
1
Common Stock
2023-09-11
4
M
0
5358
3.30
A
268794
D
Common Stock
2023-09-11
4
S
0
5358
20.01
D
263436
D
Common Stock
2023-09-12
4
M
0
300
3.30
A
263736
D
Common Stock
2023-09-12
4
S
0
300
20.00
D
263436
D
Employee Stock Option (right to buy)
3.30
2023-09-11
4
M
0
5358
0
D
2027-07-26
Common Stock
5358
86333
D
Employee Stock Option (right to buy)
3.30
2023-09-12
4
M
0
300
0
D
2027-07-26
Common Stock
300
86033
D
The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 491,569 shares of the Issuer's common stock, 376,774 of which are exercisable as of the date hereof.
The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.
/s/ Shawn Glidden, attorney-in-fact
2023-09-13